Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aslan Pharma Approved to List Shares on Taiwan's Main Board

publication date: Jan 24, 2017
Aslan Pharma of Singapore was approved to list on Taiwan's Taipei Stock Exchange, Taiwan's main board. Before being admitted to TPEX, a company must first be listed for six months on Taiwan's OTC market, sometimes known as the GreTai exchange. Aslan has met that requirement, and it will, presumably, at some point conduct a public fundraising event, though the company has not yet disclosed its plans. Founded in 2010, Aslan raised $23 million in pre-IPO venture capital last July, bringing its total VC funding to more than $100 million. More details....

Stock Symbol: (TPEX: 6497)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here